Danyang Li
Beijing, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Anti-CD123 CAR-T therapy combined with autologous SCT and venetoclax maintenance in refractory BPDCN ineligible for allogeneic transplantation: a case report and review of the literature.
Journal: Frontiers in immunology
Published: June 29, 2026
Baseline immunonutritional status drives CAR T-cell efficacy, survival, and safety in R/R lymphoma: validation of a pre-lymphodepletion PNI threshold.
Journal: Annals of hematology
Published: April 28, 2026
Impact of TP53 mutations on survival outcomes in the CAR-T era of large B-cell lymphoma.
Journal: Frontiers in immunology
Published: March 05, 2026
Overcoming chemotherapy resistance in diffuse large B-cell lymphoma using multifunctional nanocarriers: current advances and clinical challenges.
Journal: Discover nano
Published: February 07, 2026
Efficacy of BCMA CAR-T cell therapy and subsequent strategies in refractory and relapsed plasma cell leukemia: a retrospective cohort study.
Journal: Frontiers in immunology
Published: November 28, 2025
Immune microenvironment and its influence on CAR-T treatment outcomes in B-NHL.
Journal: Discover oncology
Published: November 25, 2025
CAR-T cell therapy in TP53-mutated CNS lymphoma: overcoming a high-risk genetic barrier.
Journal: Frontiers in medicine
Published: October 24, 2025
CAR T- cell therapy provides an opportunity for further consolidation treatment for relapsed or refractory adult Burkitt lymphoma patients.
Journal: Frontiers in oncology
Published: January 26, 2025
Combination autologous stem cell transplantation with chimeric antigen receptor T-cell therapy for refractory/relapsed B-cell lymphoma: a single-arm clinical study.
Journal: Frontiers in immunology
Published: November 22, 2024
Showing 1-9 of 9
Last Updated: 09/26/2026